The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Rescheduling, MSOs, cannabinoid pharma, banking. The industry as a mental health market.
DEA and HHS have moved to temporarily schedule concentrated 7-hydroxymitragynine while explicitly leaving natural kratom leaf alone, using a numeric potency threshold instead of a categorical ban. Where that threshold finally lands, and how it is measured, will determine how much of the existing kratom market ends up scheduled; the public comment window on it closed July 31.
A new multi-site trial puts tirzepatide, the metabolic GLP-1/GIP agonist, into moderate-to-severe cannabis use disorder, an indication with no approved medication. It extends an increasingly addiction-wide bet on a single reward mechanism, and for the cannabis market the same drug class is both a demand threat and a possible cure.
SB 220 took effect July 1, replacing the 5 percent THC cap, legalizing vaporization, and adding conditions. It is the biggest cannabis-policy shift since the program launched, and PTSD keeps it tied directly to the mental health debate.
The Justice Department already rescheduled medical cannabis. The June 29 to July 15 hearing considered whether the rest of the market follows, and closed without a ruling. A guide to the parties, the question before the judge, the timeline, and what each outcome does to operators.
The single most consequential line item in any cannabis operator's tax return is the disallowance under Section 280E. The April 2026 DOJ order does not eliminate it. It bifurcates it. The mechanics matter, and they are routinely misreported.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| Zygel (CBD transdermal gel) Fragile X syndrome | Harmony Biosciences | Phase 3 | RECONNECT readout; FXS program phased out |
| Epidiolex (cannabidiol) Epilepsy; behavioral indications explored | Jazz Pharmaceuticals | Approved | Additional indications under study |